Primary Hyperparathyroidism in Patients With Breast Carcinoma

Katz, Alfred D.

doi:10.1001/archsurg.1970.01340290038008

Cited by 28 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A library database search reveals no link between hyperparathyroidism (one of the most common reasons for parathyroid nuclear imaging at Duke) and breast cancer, save some case reports in the 1970s [11], making this normal-risk population ideal for our studies, where we additionally considered lowering the radiation risk from radiochemical injections to otherwise healthy volunteers. Subjects were scanned in between their routine scintigraphy (10 min post 25 mCi injection) and SPECT (2 hrs post injection) diagnostic parathyroid scans.…”

Section: Methodsmentioning

confidence: 99%

InitialIn VivoQuantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT

Mann

Perez

McCracken

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

A pilot study is underway to quantify in vivo the uptake and distribution of Tc-99m Sestamibi in subjects without previous history of breast cancer using a dedicated SPECT-CT breast imaging system. Subjects undergoing diagnostic parathyroid imaging studies were consented and imaged as part of this IRB-approved breast imaging study. For each of the seven subjects, one randomly selected breast was imaged prone-pendant using the dedicated, compact breast SPECT-CT system underneath the shielded patient support. Iteratively reconstructed and attenuation and/or scatter corrected images were coregistered; CT images were segmented into glandular and fatty tissue by three different methods; the average concentration of Sestamibi was determined from the SPECT data using the CT-based segmentation and previously established quantification techniques. Very minor differences between the segmentation methods were observed, and the results indicate an average image-based in vivo Sestamibi concentration of 0.10 ± 0.16 μCi/mL with no preferential uptake by glandular or fatty tissues.

show abstract

Section: Methodsmentioning

confidence: 99%

InitialIn VivoQuantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT

Mann

Perez

McCracken

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…The increased relative risk of breast and renal carcinomas is difficult to explain by any bias, although only sporadic cases with an association with hyperparathyroidism have been reported (2,(8)(9)(10).…”

Section: Relative Risk By Observation Timementioning

confidence: 99%

Increased Risk of Malignant Diseases After Surgery for Primary Hyperparathyroidism

Palmér¹,

Adami²,

Krusemo

et al. 1988

American Journal of Epidemiology

View full text Add to dashboard Cite

A cohort of 4,163 persons reported to the nationwide Swedish Cancer Registry by reason of hyperparathyroidism was followed for up to 22 completed years (24,593 person-years of observation). The occurrence of malignant disease manifested after parathyroid surgery was investigated through computerized linkage to the entire Cancer Registry. During the entire period, the hyperparathyroidism patients suffered malignant diseases significantly more often than the background population (relative risk (RR) = 1.6, 95% confidence interval (CI) 1.5-1.8). Even if all cases with malignant diseases detected at the same time as hyperparathyroidism or during the first year after parathyroid surgery were eliminated, a significantly increased risk remained for the following years (RR = 1.4, 95% CI 1.2-1.6). A significantly increased relative risk of developing gastrointestinal cancers, endocrine tumors, kidney carcinomas, and mammary carcinomas was found. During the first postoperative year, an increased surveillance of the cohort is likely to have contributed to the increased risk, but detection bias is considered unlikely to be the only explanation for the higher risk during all subsequent years. The findings indicate that hyperparathyroidism either promotes later development of malignant tumors or that this condition and certain malignant diseases have etiologic factors in common.

show abstract

“…The two tumours reported here, carcinoma of the breast and retroperitoneal sarcoma, were not included in their list. Katz et al (1970), in describing primary hyperparathyroidism in patients with breast cancer, commented on the frequency of hypercalcaemia in that condition and on the absence of any report of the occurrence of parathyroid hormone-like material in a cancer arising from the breast.…”

Section: Tissue Assay and Resultsmentioning

confidence: 99%

Parathyroid hormone production and malignancy.

Melick¹,

Martin²,

Hicks³

1972

BMJ

View full text Add to dashboard Cite

period in the first test was taken as 100% the mean (± S.E. of the mean) change found in the second test was 13-25% (±6 0%) for the plateau acid output, 7.85% (±5.81%) for the peak acid output, and 13.88% (±9-14%) for the total acid output. DiscussionOur data indicate that the administration of insulin by a continuous infusion technique does produce a steady-state acid secretion in response to a steady level of hypoglycaemia.Although additional dose-response data will be required our initial trial indicates that a dose of 0 04 U of insulin/kg/hr produces the highest plateau of acid secretion associated with relatively few hypoglycaemic symptoms. It also appears important not to prolong the fasting period over 12 hours. It is as yet too early to reach any definitive conclusions about the ultimate value of the continuous insulin infusion test, but it already appears safe and is associated with few side effects. It is hoped that by producing a steady state as opposed to a peak secretory response its interpretation will be facilitated.The applicability of the criteria currently used for the conventional Hollander test (Hollander, 1946) and the definition of new criteria are at present being evaluated.We are grateful to Professor A. P. M. Forrest for his encouragement in the development of this test, to Dr. I.

show abstract

Primary Hyperparathyroidism in Patients With Breast Carcinoma

Cited by 28 publications

References 20 publications

InitialIn VivoQuantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT

InitialIn VivoQuantification of Tc-99m Sestamibi Uptake as a Function of Tissue Type in Healthy Breasts Using Dedicated Breast SPECT-CT

Increased Risk of Malignant Diseases After Surgery for Primary Hyperparathyroidism

Parathyroid hormone production and malignancy.

Contact Info

Product

Resources

About